Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition –An Outstanding Challenge

Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge Attila Fintha1, Ákos Gasparics2, László Rosivall3 and Attila Sebe3,4* 12nd Department of Pathology, Semmelweis University, Budapest, Hungary 21st Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary 3Department of Pathophysiology, International Nephrology Research and Training Center, Semmelweis University, Budapest, Hungary 4Division of Medical Biotechnology, Paul Ehrlich Institute, Langen, Germany Back in 1995, a landmark paper was published, which shaped the fibrosis literature for many years to come. During the characterization of a fibroblast-specific marker (FSP1) in the kidneys, an observation was made, which gave rise to the hypothesis that “fibroblasts in some cases arise from the local conversion of epithelium.” In the following years, epithelial-mesenchymal transition was in the spotlight of fibrosis research, especially in the kidney. However, the hypothesis came under scrutiny following some discouraging findings from lineage tracing experiments and clinical observations. In this review, we provide a timely overview of the current position of the epithelial-mesenchymal transition hypothesis in the context of fibrosis (with a certain focus on renal fibrosis) and highlight some of the potential hurdles and pitfalls preventing therapeutic breakthroughs targeting fibrotic epithelial-mesenchymal t...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research

Related Links:

Source: Biological Rhythm Research - Category: Research Authors: Source Type: research
Publication date: Available online 13 July 2020Source: Pathology - Research and PracticeAuthor(s): Hyun Ji Son, Ha Yoon Mo, Nam Jin Yoo, Sug Hyung Lee
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: Available online 13 July 2020Source: Pathology - Research and PracticeAuthor(s): Jamal Halajzadeh, Parisa Maleki Dana, Zatollah Asemi, Mohammad Ali Mansournia, Bahman Yousefi
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Conclusion: Lactobacillus acidophilus strains given as probiotic were not able to reduce serum levels of uremic toxins and biomarkers of inflammation in CKD patients in stage 3 and 4.
Source: Current Nutrition and Food Science - Category: Nutrition Source Type: research
Conclusion: Only one third reached dietary intake of folate, but deficiencies of folate and B12 were low. Psoriasis severity was negatively correlated with circulating folate and B12. Stopping smoking and a folate rich diet may be important targets for managing psoriasis.
Source: Current Nutrition and Food Science - Category: Nutrition Source Type: research
Conclusion: FN made in the 4:3:3 ratio of powder of corn, powder of bean cake defatted and powder of peeled whole potato is more effective to decrease the levels of postprandial 2h-blood glucose. FN is a staple type of functional food that could be used for the treatment of IGT.
Source: Current Nutrition and Food Science - Category: Nutrition Source Type: research
BOWEL cancer affects a person's digestive system in a number of ways. Tenesmus is one of the warning symptoms relating to digestion. The condition could signal early bowel cancer. What is tenesmus?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Could this technique help promote wound healing among oncology patients with complex wounds?Wounds
Source: Medscape Today Headlines - Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news
Conclusions: Azathioprine can stabilize or improve CTD-ILD. While early drug intolerance is frequent, most patients who have tolerated the drug well achieve long-term stabilization or improvement of lung function.Respiration
Source: Respiration - Category: Respiratory Medicine Source Type: research
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its investigational CD20xCD3 T-cell engaging bispecific mosunetuzumab has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma who have received at least two prior systemic therapies.“We are pleased that the FDA has granted Breakthrough Therapy Designation to mosunetuzumab, recognising the promising early efficacy data for this molecule and the remaining unmet need in follicular lymphoma,” said Levi Gar...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Autoimmune Disease | Avapro | Biotechnology | Bone Marrow Aspiration and Biopsy | Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Chemistry | Chronic Kidney Disease | Cirrhosis | Cleft Palate | Clinical Trials | Cozaar | Dermatology | Diabetes | Diabetes Type 2 | Diabetic Ulcers | Drugs & Pharmacology | Endocrinology | Environmental Health | Epidemics | Epidemiology | Epithelial Cancer | Finland Health | Gastroschisis Repair | Genetics | Germany Health | Glomerulonephritis | Heart | Hepatitis | Hepatitis B | Hungary Health | Hypertension | Interstitial Lung Disease | Liver | Losartan | Men | Molecular Biology | Nephrectomy | Nephrotic Syndrome | Neurology | Neuroscience | OBGYN | Pathology | Polycystic Kidney Disease | Proteinuria | Rheumatology | Scleroderma | Skin | Skin Biopsy | Skin Graft | Stem Cell Therapy | Stem Cells | Study | Tetracycline | Thyroid | Thyroid Cancer | Toxicology | Training | Translocation | Universities & Medical Training | Ureter and Renal Pelvis Cancer | Urology & Nephrology